Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Eisai's Regional Shift, Or Just Restructuring? Daiichi Sankyo's U.S. Ranbaxy Dip: Japanese Earnings Roundup (Part 2 of 2)

This article was originally published in PharmAsia News

Executive Summary

[Editor's note: This is part two of a two-part feature on Japanese pharma earnings; part one covered Dainippon Sumitomo Pharma Co. Ltd. and its failed pan-Asia trials and Mitsubishi Tanabe Pharma Corp.'s efforts to rebound from Japan's March 11 earthquake. This second part covers Eisai Co. Ltd. and Daiichi Sankyo Co. Ltd.]

Related Content




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts